Marker Therapeutics, Inc. (MRKR)
NASDAQ · Healthcare
Marker Therapeutics, Inc. Operating Income 2017–2025
Marker Therapeutics, Inc. annual/quarterly operating income history and growth rate from 2017 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Marker Therapeutics, Inc. operating income for the quarter ending March 31, 2026 was -4.1 M, a 17.86% decrease year-over-year.
- Marker Therapeutics, Inc. operating income for the twelve months ending March 31, 2026 was -15.4 M, a 47.54% increase year-over-year.
- Marker Therapeutics, Inc. annual operating income for 2025 was -12.9 M, a 15.94% increase from 2024.
- Marker Therapeutics, Inc. annual operating income for 2024 was -11.1 M, a 23.75% decrease from 2023.
- Marker Therapeutics, Inc. annual operating income for 2023 was -14.6 M, a 26.32% decrease from 2022.
- Marker Therapeutics, Inc. annual operating income for 2022 was -19.8 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Marker Therapeutics, Inc. Operating Income — FAQ
Marker Therapeutics, Inc. (MRKR) operating income over the last 9 years — annual and quarterly figures with year-over-year growth and charts.
What is Marker Therapeutics, Inc.'s operating income?
Marker Therapeutics, Inc. (MRKR) reported operating income of -$13M for fiscal 2025.
Where can I see MRKR's operating income history?
The chart and table above show Marker Therapeutics, Inc.'s operating income by year and by quarter, including the growth rate.